Abstract:Cardiac hypertrophy is characterized by an increase in cell size in the absence of cell division and is accompanied by a number of qualitative and quantitative changes in gene expression. Most forms of hypertrophy in vivo are compensatory or adaptative responses to increased workload resulting from various physiological and/or pathological etiologies. Until severe pathological alterations become apparent, myocytes show no drastic morphological changes. On the level of gene expression, upregulation of the so-called fetal genes, i.e., beta-myosin heavy chain, alpha-skeletal and alpha-smooth muscle actin, and atrial natriuretic factor (ANF) may be observed concomitant with a downregulation of alpha-myosin heavy chain and the Ca pump of sarcoplasmic reticulum. The use of primary cell culture systems for cardiomyocytes as an in vitro model for the hypertrophic reaction has identified a number of different stimuli as mediators of cardiac myocyte hypertrophy. The molecular dissection of the different intracellular signaling pathways involved herein has uncovered a number of branching points to cytosolic and nuclear targets and has identified many interactions between these pathways. The individual administration of these hypertrophic stimuli, i.e., hormones, cytokines, growth factors, vasoactive peptides, and catecholamines, to cultured cardiomyocytes, reveals that each stimulus induces a distinct phenotype as characterized by gene expression pattern and cellular morphology. Surprisingly, triiodothyronine (T3) and basic fibroblast growth factor (bFGF) effect a similar cellular phenotype although they use completely different intracellular pathways. This phenotype is characterized by drastic inhibition of myofibrillar growth and by upregulation of alpha-smooth muscle actin. On the other hand, insulin-like growth factor (IGF) I, a factor promoting muscle cell differentiation, and bFGF, an inhibitor of differentiation, cause completely different cardiomyocyte phenotypes although both are known to signal via receptor tyrosine kinases and have been shown to activate the Ras-Raf-MEK-MAP kinase pathway. However, both IGF-I and bFGF depend on T3 to bring about their typical responses, i.e., T3 is permissive for the action of these two growth factors on the expression of alpha-smooth muscle actin and cell morphology. Most of the hypertrophic stimuli are balanced under normal circumstances in vivo. When this balance is disturbed, however, a pathological heart phenotype may become dominant. Thus the knowledge of signaling pathways and cellular responses triggered by hypertrophic stimuli may be essential for the implementation of therapeutic strategies in the treatment of cardiac hypertrophy.

Cellular signal transduction in cardiac hypertrophy

[Signal Transduction Pathways in Cardiac Myocyte Hypertrophy].

Role of Mitogen-Activated Protein Kinase in Myocardial Hypertrophy

Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Increased Myocardial Stiffness Activates Cardiac Microvascular Endothelial Cell Via VEGF Paracrine Signaling in Cardiac Hypertrophy

Alteration of mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated heart failure with preserved ejection fraction.

Inhibitory Molecules in Signal Transduction Pathways of Cardiac Hypertrophy

Transforming growth factor-β and bone morphogenetic protein signaling pathways in pathological cardiac hypertrophy

Angiotensin II-Induced Signal Transduction Mechanisms for Cardiac Hypertrophy

Deciphering transcriptional dynamics of cardiac hypertrophy and failure in a chamber-specific manner

Ca2+—Dependent Signaling Pathways Through Calcineurin and Ca2+ Calmodulin—Dependent Protein Kinase in Development of Cardiac Hypertrophy

Mechanisms of physiological and pathological cardiac hypertrophy

Second Messenger Systems Involved in Heart Mechanotransduction

Role of extracellular signal-regulated kinase 1/2 signaling underlying cardiac hypertrophy

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy

Toll-like receptors in cardiac hypertrophy

The role and molecular mechanism of epigenetics in cardiac hypertrophy

Mitochondrial function in cardiac hypertrophy.

Differential cardiac hypertrophy and signaling pathways in pressure versus volume overload.

Transcription Factors Involved in the Development and Prognosis of Cardiac Remodeling